Altuviiio (FVIII Rec,Fc-VWF-Xten,Bdd-Ehtl) Patent Expiration, LOE Window & CMS Spending

Altuviiio (FVIII Rec,Fc-VWF-Xten,Bdd-Ehtl) by Sanofi: Off-Patent Genericized (AB Competition), 0 AB generics, $198.7M 2024 CMS Part D & Medicaid spend, and $5 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSanofi
FDA Application & PathwayReconciled (UNLINKED)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$198.7M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$198.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($5 intro WAC)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Sanofi across sibling Meru public-data platforms.